Immunotoxins for treatment of intracranial lesions and as adjunct to chemotherapy
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsVirginia Johnson, Richard J. Youle
Life of this patent
Estimating the term…
Abstract
A potent and specific immunotoxin is prepared by coupling a binding-site inactivated diphtheria toxin (CRM 107) to a new binding moiety consisting of transferrin or a monoclonal antibody against the human transferrin receptor. These immunotoxins are tumor specific and lack the nonspecific toxicity produced by the binding activity of the native toxin. The immunotoxin is useful in treating primary brain tumors, metastatic tumors to the brain, CSF-borne tumors, leptomeningeal leukemia and leptomeningeal carcinomatosis.
Claims10
A method of treating central nervous system tumors or prophylaxing against metastatic lesions to the central nervous system comprising administering a tumor-inhibiting amount of a conjugate comprising a diphtheria toxin, wherein said diphtheria toxin lacks an active cell binding activity, attached to a moiety which binds to transferrin receptors, wherein said moiety which binds to transferrin receptors is selected from the group consisting of an anti-transferrin receptor antibody and transferrin, and wherein the mode of administration is intracranial or intrathecal.
Dependencies are inferred from the claim text.